Skip to main content

Icon Legend
Presentation Icons
Ticketed Event
Ticketed Event
In Person Only
In Person Only
Location: Hilton San Diego Bayfront
Location: Hilton San Diego Bayfront

Abstracts

Abstracts

  • Wednesday, October 4, 2023
  • 8:00 AM – 8:07 AM PT
    264 - Efficacy and Toxicity of Different Target Volume Delineations of Radiotherapy Based on the Updated RTOG/NRG and EORTC Guidelines in Patients with High Grade Glioma: A Randomized, Controlled Clinical T
    Location: Room 33

    Presenter: Feng Liu, MD – Hunan Cancer Hospital

  • 8:10 AM – 8:17 AM PT
    265 - Low Dose Fractionated Radiation Therapy as a Chemo-Potentiator of Salvage Temozolomide (TMZ) for Recurrent Anaplastic Astrocytoma (AA) and Glioblastoma Multiforme (GBM): A Single-Arm Phase I/II Trial
    Location: Room 33

    Presenter: Timothy Lin, MD, MBA – Johns Hopkins University

  • 8:20 AM – 8:27 AM PT
    266 - Multi-Institutional Report of Re-Irradiation for Recurrent High-Grade Glioma
    Location: Room 33

    Presenter: Hosniya Zarabi, MD, MS, BS – Wake Forest Baptist Medical Center

  • 8:30 AM – 8:37 AM PT
    267 - Oncogenic Activities of Tribbles1 (TRIB1) Pseudokinase Overexpressed in GBM Are Mediated By Protein-Protein Interactions
    Location: Room 33

    Presenter: Karnika Singh, PhD – OSU CCC

  • 8:40 AM – 8:47 AM PT
    268 - A Combined Phase 0/2 "Trigger" Trial of Niraparib in Combination with Radiation in Patients with Newly-Diagnosed Glioblastoma
    Location: Room 33

    Presenter: William Kennedy, MD – Barrow Neurological Institute

  • 8:50 AM – 9:00 AM PT
    Discussant
    Location: Room 33

    Discussant: Jennifer Yu, MD, PhD – Cleveland Clinic Taussig Cancer Center

  • 8:05 AM – 8:10 AM PT
    1206 - Very Low Dose Radiation Therapy for Indolent Lymphomas: Comparing "Big Boom" (4Gy x 1) vs. "Boom Boom" (2Gy x 2)
    Location: Room 8

    Presenter: Brandon Imber, MD, MS – Memorial Sloan Kettering Cancer Center

  • 8:10 AM – 8:15 AM PT
    1208 - Distribution and Failure Patterns of Primary Central Nervous System Lymphoma Related to Hippocampus
    Location: Room 8

    Presenter: Hye-Jo Ryu, MD – Seoul National University

  • 8:15 AM – 8:20 AM PT
    1210 - Acute Pulmonary Toxicity after Allogeneic Stem Cell Transplantation Using Total Body Irradiation-Based Conditioning- Myeloablative vs. Non-Myeloablative Regimens
    Location: Room 8

    Presenter: Christopher Kelsey, MD, FASTRO – Duke University Medical Center

  • 8:20 AM – 8:25 AM PT
    1212 - Irradiated Extramedullary Acute Myeloid Leukemia Increases Survival in a Leukemic Mouse Model
    Location: Room 8

    Presenter: Francisco Saenz, PhD, MS – University of Texas MD Anderson Cancer Center

  • 8:25 AM – 8:30 AM PT
    1214 - First-in-Human Phase I Trial Combining Biologically Guided Radioimmunotherapy (RIT) Using a 90Y-Anti-CD25 Monoclonal Antibody (Mab) with CT-guided Total Marrow and Lymphoid Irradiation (TML
    Location: Room 8

    Presenter: Jeffrey Wong, MD, FASTRO – City of Hope National Medical Center

  • 8:30 AM – 8:35 AM PT
    1216 - Long-Term Toxicity after Total Body Irradiation-Based Conditioning Regimens for Allogeneic Stem Cell Transplantation
    Location: Room 8

    Presenter: Pranalee Patel, MD, BS – Duke University School of Medicine

  • 8:05 AM – 8:10 AM PT
    1218 - Failure Mode and Effects Analysis for Treatment Workflow of a Novel Ring Gantry Linac
    Location: Room 7

    Presenter: Shada Wadi-Ramahi, PhD – University of Pittsburgh, Hillman Cancer Center

  • 8:10 AM – 8:15 AM PT
    1220 - ACR Accreditation of a Novel Linac-Based kV-CBCT System on a High-Speed Ring-Gantry
    Location: Room 7

    Presenter: Allison Haertter, MS – New York Proton Center

  • 8:15 AM – 8:20 AM PT
    1222 - Dosimetric Comparison of Adaptive Radiotherapy Modalities for Stereotactic Partial Breast Irradiation
    Location: Room 7

    Presenter: Yesenia Gonzalez, PhD – UT Southwestern Medical Center

  • 8:20 AM – 8:25 AM PT
    1224 - Extended Field Radiosurgery of Spinal Metastases with MRI-Guided Adaptive Planning: A Dosimetric Study
    Location: Room 7

    Presenter: Beatriz Guevara, MS – Sylvester Comprehensive Cancer Center

  • 8:25 AM – 8:30 AM PT
    1226 - Predicting Prostate VMAT 3D Radiation Doses of Continuously Varying Organ Dose Trade-Offs Using a Conditional Variational Autoencoder
    Location: Room 7

    Presenter: Simeng Zhu, MD – Ohio State University James Cancer Hospital

  • 8:30 AM – 8:35 AM PT
    1228 - Brachytherapy Dose Prediction Based on Monte Carlo Simulations Using Artificial Neural Networks
    Location: Room 7

    Presenter: Zhen Li, MS – Shanghai Sixth People's Hospital

  • 9:15 AM – 9:45 AM PT
    Discussant
    Location: Ballroom 20

    Discussant: Kimmie Ng, MD, MPH – Dana-Farber Cancer Institute / Harvard Medical School

  • 9:45 AM – 10:15 AM PT
    Discussant
    Location: Ballroom 20

    Discussant: Kristy Brock, PhD, FASTRO – MD Anderson Cancer Center

  • 10:30 AM – 10:37 AM PT
    269 - More Efficient Auto-Segmentation Framework Using Patient-Specific Information for CBCT-Guided Adaptive Radiotherapy
    Location: Room 5

    Presenter: Yuxiang Liu, MS – ASTRO Show Management

  • 10:40 AM – 10:47 AM PT
    270 - New Data-Driven Gated (DDG) PET/CT for Radiation Treatment Planning of NSCLC
    Location: Room 5

    Presenter: Tinsu Pan, PhD – MD Anderson Cancer Center

  • 10:50 AM – 10:57 AM PT
    271 - Failure Mode and Effects Analysis Prior to the Introduction of AI Generated GTVs for Brain Metastases in the Clinical Workflow
    Location: Room 5

    Presenter: Michalis Aristophanous, PhD – Memorial Sloan Kettering Cancer Center

  • 11:00 AM – 11:07 AM PT
    272 - An Automated Brain Metastasis Detection and Segmentation System from MRI with a Large Multi-Institutional Dataset
    Location: Room 5

    Presenter: Youngjin Yoo, PhD – Siemens Healthineers

  • 11:10 AM – 11:17 AM PT
    273 - Clinical Outcomes of Image-Guided Volumetric Modulated Arc Therapy for Total Body Irradiation
    Location: Room 5

    Presenter: Sarah Kilic, MD, MS – Arizona Oncology

  • 11:20 AM – 11:27 AM PT
    274 - Dosimetric and Clinical Results of a Volumetric-Based Skin-Sparing Planning Technique for Patients Treated to the Breast and Chest Wall with Pencil Beam Scanning Proton Therapy
    Location: Room 5

    Presenter: Avani Rao, MD – Radiation Oncology Associates

  • 10:30 AM – 10:37 AM PT
    275 - Patient-Level Savings Using the Mark Cuban Cost Plus Drugs Company for Radiation Oncology Patients
    Location: Room 4

    Presenter: Ramez Kouzy, MD – MD Anderson Cancer Center

  • 10:40 AM – 10:47 AM PT
    276 - Clinical Sequalae of Initial Insurance Denials in a Large Academic Radiation Oncology Center
    Location: Room 4

    Presenter: Jacob Shin, MD – Memorial Sloan Kettering Cancer Center

  • 10:50 AM – 10:57 AM PT
    277 - Association of Managed Medicaid Plans and Cancer Stage at Diagnosis
    Location: Room 4

    Presenter: Justin Barnes, MD, MS – Washington University School of Medicine

  • 11:00 AM – 11:07 AM PT
    278 - Comparing Changes in Medicare Reimbursement for Radiation Oncology and Medical Oncology (2010-2020)
    Location: Room 4

    Presenter: Jacob Hogan, BS – Washington University in St. Louis School of Medicine

  • 11:10 AM – 11:17 AM PT
    279 - Financial Improvements from Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care, "SAVE" Trial
    Location: Room 4

    Presenter: Cristina DeCesaris, MD – University of Utah Huntsman Cancer Institute

  • 11:20 AM – 11:27 AM PT
    280 - Unplanned Hospitalization and Subsequent Mortality in Lung Cancer Patients Undergoing Concomitant Chemo-/Immuno-Therapy and Radiotherapy: An Analysis of Over 10,000 Patients in a Nationwide Database
    Location: Room 4

    Presenter: Jongmyung Kim, MD, PhD – Rutgers Cancer Institute of New Jersey

  • 10:35 AM – 10:40 AM PT
    1230 - Hybrid Immuno-RT for Bulky Tumors: Standard Fractionation with Partial Tumor SBRT
    Location: Room 8

    Presenter: Ren Luo, MD, PhD – Huaxi Hospital

  • 10:40 AM – 10:45 AM PT
    1232 - Fungal Depletion Bolsters Anti-Tumor Immune Response Elicited by Anti-PD1 Alone and in Combination with Radiation Therapy
    Location: Room 8

    Presenter: Satchel Stevens, BS – Cedars-Sinai Medical Center

  • 10:45 AM – 10:50 AM PT
    1234 - Non-Canonical NF-kB Pathway Suppresses Anti-Tumor Micro-environment and Prompts Pre-Metastasis Niches for Conventional Fractionated Radiotherapy
    Location: Room 8

    Presenter: Dawei Chen, MD, MB

  • 10:50 AM – 10:55 AM PT
    1236 - Irradiated Tumor Cells-derived Exosomes Modulate Macrophage Polarization by Targeting SHP-2 Mediated Metabolic Reprogramming
    Location: Room 8

    Presenter: Dawei Chen, MD, MB

  • 10:55 AM – 11:00 AM PT
    1238 - Radiation Therapy Sensitizes Head-and-Neck Cancer Cells to Killing by Chimeric Antigen Receptor (CAR)-NK Cells Targeting CD70
    Location: Room 8

    Presenter: Gohar Manzar, MD, PhD – MD Anderson Cancer Center

  • 11:00 AM – 11:05 AM PT
    1240 - Malignant Peripheral Nerve Sheath Tumors Activate Distinct Immunosuppressive Pathways Following Radiotherapy and are Associated with Immune Depletion In Vivo
    Location: Room 8

    Presenter: Iowis Zhu, PhD – University of California, San Francisco

  • 10:35 AM – 10:40 AM PT
    1242 - Evaluation of Pneumonitis in a Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilmumab or Nivolumab Alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non
    Location: Room 7

    Presenter: Michael Weisman, MD – IU Health Methodist Hospital

  • 10:40 AM – 10:45 AM PT
    1244 - A Novel FDG PET and Mean Lung Dose Model to Identify Stage III NSCLC Patients at High Risk of Developing Early Radiation Pneumonitis
    Location: Room 7

    Presenter: Maria Thor, PhD, MS – Memorial Sloan Kettering Cancer Center

  • 10:45 AM – 10:50 AM PT
    1246 - Association of Cardiac Dose with Cardiac Events and Survival for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Treated with Concurrent Chemoradiotherapy (cCRT) in the Era of Immune Checkpoint
    Location: Room 7

    Presenter: Nikhil Yegya-Raman, MD – University of Pennsylvania Health System

  • 10:50 AM – 10:55 AM PT
    1248 - Investigating Dosimetry and Imaging Biomarkers for Prediction of Major Adverse Cardiac Events Following Locally Advanced Non-Small Cell Lung Cancer Radiotherapy
    Location: Room 7

    Presenter: Hyunsoo No, MD, CMD – Stanford University

  • 10:55 AM – 11:00 AM PT
    1250 - Association of Left Ventricular Myocardium Dose Exposure with Heart Failure in Lung Cancer Radiotherapy
    Location: Room 7

    Presenter: Katelyn Atkins, MD, PhD – Cedars-Sinai Medical Center

  • 11:00 AM – 11:05 AM PT
    1252 - Long-Term Toxicity in Patients Receiving Radiotherapy for Ultracentral Stage I Non-Small Cell Lung Cancer - A Secondary Analysis of the LUSTRE Randomized Trial
    Location: Room 7

    Presenter: Che Hsuan David Wu, MD – BC Cancer Agency - Vancouver Island Centre

  • 10:30 AM – 10:37 AM PT
    281 - Health-Related Quality of Life at Five Years for a Randomized Trial of Tri-Modality Therapy with I-125 Brachytherapy, External Beam Radiation Therapy, and Short- vs. Long-Term Androgen Deprivation The
    Location: Room 1

    Presenter: Atsunori Yorozu, MD, PhD – National Hospital Organization Tokyo Medical Center

  • 10:40 AM – 10:47 AM PT
    282 - Patient-Reported Urinary and Bowel Quality of Life Outcomes Following External Beam Radiotherapy with or without High-Dose-Rate Brachytherapy Boost: Post-Hoc Analyses of TROG 03.04 (RADAR)
    Location: Room 1

    Presenter: Wee Loon Ong, MBBS – Alfred Health Radiation Oncology

  • 10:50 AM – 10:57 AM PT
    283 - Conditional Risk and Predictive Factors Associated with Late Toxicity for Prostate Cancer Patients Treated with External Beam Radiotherapy Alone on Randomized Trial RTOG 0126
    Location: Room 1

    Presenter: Gregory Alexander, MD – Thomas Jefferson University

  • 11:00 AM – 11:07 AM PT
    284 - Late Urinary Toxicity and QOL with Curative Radiotherapy for High-Risk Prostate Cancer: Dose-Effect Relations in the POP-RT Randomized Phase III Trial
    Location: Room 1

    Presenter: Priyamvada Maitre, MD – The Christie NHS Foundation Trust

  • 11:10 AM – 11:17 AM PT
    285 - Toxicity and Patient Reported Quality of Life after PSMA-PET and mpMRT-Based Focal Dose Escalated Definitive Radiotherapy in Prostate Cancer Patients: 2-Year Follow-Up of the HypoFocal Phase II Trial
    Location: Room 1

    Presenter: Simon Spohn, MD – University Medical Center Freiburg

  • 11:20 AM – 11:27 AM PT
    286 - Patient Reported Outcomes in High-Risk Prostate Cancer Patients with or without Testosterone Recovery after Androgen Deprivation Therapy
    Location: Room 1

    Presenter: Abdenour Nabid, MD – CHUS

  • 11:30 AM – 11:40 AM PT
    Discussant
    Location: Room 1

    Presenter: William Jackson, MD – University of Michigan

  • 10:30 AM – 10:37 AM PT
    287 - Treatment Terminations during Radiation Therapy: A Ten-Year Experience
    Location: Room 2

    Presenter: Jason Nosrati, MD – Northwell Health Center for Advanced Medicine

  • 10:40 AM – 10:47 AM PT
    288 - Quantitative and qualitative impact of CT-Based Radiotherapy Dose Maps on Radiologists Interpretation of Post-treatment Thoracic Surveillance Imaging
    Location: Room 2

    Presenter: Kira Newell, BA – University of Washington School of Medicine

  • 10:50 AM – 10:57 AM PT
    289 - Quality Assurance in a Phase III, Multicenter, Randomized Trial of POstmastectomy radioThErapy in Node posiTive Breast Cancer with or without Internal mAmmary nodaL Irradiation (POTENTIAL): A Planning
    Location: Room 2

    Presenter: Yuchun Song, MD – Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

  • 11:00 AM – 11:07 AM PT
    290 - Reducing Patient Care Delays in Radiation Oncology via Optimization of Insurance Pre-Authorization
    Location: Room 2

    Presenter: Maxwell Tran, MD – MUSC

  • 11:10 AM – 11:17 AM PT
    291 - Optimization of Workup Pathways to Decrease Radiotherapy Wait Times and Improving Patient Experience: A Single Center Study
    Location: Room 2

    Presenter: Abdulmajeed Dayyat, MD

  • 11:20 AM – 11:27 AM PT
    292 - Can We Improve the Quality of Care Delivered to Cervical Cancer Patients? Development of Quality Metrics and Quality Improvement Program at a Single Institution
    Location: Room 2

    Presenter: Sudha Amarnath, MD – Cleveland Clinic Taussig Cancer Center

  • 11:30 AM – 11:40 AM PT
    Discussant
    Location: Room 2

    Discussant: Manju Sharma, PhD – University of California, San Francisco

  • 12:30 PM – 12:37 PM PT
    293 - Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients: Final Results of a Phase I Trial
    Location: Room 1

    Presenter: Christophe Le Tourneau, MD, PhD – Institut Curie

  • 12:40 PM – 12:47 PM PT
    294 - Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Locally Advanced Laryngeal/Hypopharyngeal Carcinoma: Preliminary Results of INSIGHT Study
    Location: Room 1

    Presenter: Xiaomin Ou, MD – Fudan University Shanghai Cancer Center

  • 12:50 PM – 12:57 PM PT
    295 - SBRT in 3 Fractions for T1 Glottic Cancer
    Location: Room 1

    Presenter: Giuseppe Sanguineti, MD, Mr – Regina Elena National Cancer Institute

  • 1:00 PM – 1:07 PM PT
    296 - Identifying a Dose Constraint for the Parotid Ducts: Impact on Patient Reported Xerostomia and Comparison to Conventional Parotid Gland Mean Dose Sparing
    Location: Room 1

    Presenter: Shiva Das, PhD – University of North Carolina

  • 1:10 PM – 1:17 PM PT
    297 - Dose Painting Radiotherapy Guided by Diffusion-Weighted Magnetic Resonance vs. 18F-FDG-PET/CT in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized, Controlled Clinical Trial
    Location: Room 1

    Presenter: Feng Liu, MD – Hunan Cancer Hospital

  • 1:20 PM – 1:30 PM PT
    Discussant
    Location: Room 1

    Discussant: Michelle Mierzwa, MD – University of Michigan

  • 12:35 PM – 12:40 PM PT
    1254 - Intracranial Control with Combined Dual Immune-Checkpoint Blockade and SRS for Melanoma and NSCLC Brain Metastases
    Location: Room 7

    Presenter: Eugene Vaios, MD, MBA – Duke Cancer Institute

  • 12:40 PM – 12:45 PM PT
    1256 - Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): One-Year Safety and Efficacy Outcomes From a Multicenter Phase I Trial
    Location: Room 7

    Presenter: Shearwood McClelland, MD – University Hospitals Cleveland

  • 12:45 PM – 12:50 PM PT
    1258 - Initial Report of Boswellia Serrata for Management of Cerebral Radiation Necrosis After Stereotactic Radiosurgery for Brain Metastases
    Location: Room 7

    Presenter: Rituraj Upadhyay, MD, MBBS, DNB – Ohio State University

  • 12:50 PM – 12:55 PM PT
    1260 - Frameless LINAC-Based Stereotactic Radiosurgery is Safe and Effective for Essential and Parkinsonian Tremor
    Location: Room 7

    Presenter: Nii-Kwanchie Ankrah, MD – University of Alabama Birmingham Hospital

  • 12:55 PM – 1:00 PM PT
    1264 - Volumetric Modulated Arc Therapy Craniospinal Irradiation Utilizing a Vertebral Body Sparing Approach: A Toxicity Analysis
    Location: Room 7

    Presenter: Jennifer Matsui, PhD – The Ohio State

  • 1:05 PM – 1:10 PM PT
    2236 - Feasibility of Cognitive-Sparing Stereotactic Radiosurgery for Brain Metastases: Initial Report of Phase II COG-SRS Trial
    Location: Room 7

    Presenter: Austin Hopper, MD – UCSD Radiation Medicine and Applied Sciences

  • 12:35 PM – 12:40 PM PT
    1266 - Very APBI in 1 or 2 Days: Late Toxicity and Early Oncological Outcomes of the GEC-ESTRO Cohort
    Location: Room 8

    Presenter: Jean-Michel Hannoun-Levi, MD, PhD

  • 12:40 PM – 12:45 PM PT
    1268 - Proton vs. Photons for Breast Cancer Patients with Immediate, Implant-Based Reconstruction Receiving Postmastectomy Radiotherapy: A Multicenter Pooled Analysis
    Location: Room 8

    Presenter: Myrsini Ioakeim-Ioannidou, MD – Massachusets General Hospital

  • 12:45 PM – 12:50 PM PT
    1270 - A Phase II Randomized Clinical Trial to Assess Toxicity and Quality of Life of Breast Cancer Patients with Hypofractionated vs. Conventional Fractionation Radiotherapy with Regional Nodal Irradiation
    Location: Room 8

    Presenter: Gabriel Gil, MD, PhD, MBA, MS – Rede Mater Dei

  • 12:50 PM – 12:55 PM PT
    1272 - Cardiological Safety of 5-Fraction Whole Breast Irradiation
    Location: Room 8

    Presenter: Lorenzo Livi, MD

  • 12:55 PM – 1:00 PM PT
    1274 - Pattern and Complication of Reconstructed Breast Cancer Patients Who Received Postmastectomy Radiotherapy in the National Health Insurance Service Cohort
    Location: Room 8

    Presenter: Hye-Jo Ryu, MD – Seoul National University

  • 1:00 PM – 1:05 PM PT
    1276 - Identification and Dosimetric Analysis of Axillary Substructures Associated with Breast Cancer Related Lymphedema
    Location: Room 8

    Presenter: Jia-Qi Huang

  • 12:30 PM – 12:37 PM PT
    305 - Risk of Sexual Dysfunction in Men Treated with Pelvic Radiation Therapy for Locally Advanced Rectal Cancer: 20 Years of Experience with 430 Patients
    Location: Room 4

    Presenter: Kush Patel, BA, MBS – Memorial Sloan Kettering Cancer Center

  • 12:40 PM – 12:47 PM PT
    306 - Prognostic Role and Time Varying Failure Hazard of Neoadjuvant Rectal (NAR) Scores in the Stellar Randomized Phase 3 Trial
    Location: Room 4

    Presenter: Yuan Tang, MD – Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College

  • 12:50 PM – 12:57 PM PT
    307 - Relationships between Microbiome and Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer
    Location: Room 4

    Presenter: Bum Sup Jang, MD, PhD – Seoul National University Hospital

  • 1:00 PM – 1:07 PM PT
    308 - Long-Term Anorectal Function in Rectal Cancer Patients Managed by a Watch-and-Wait Strategy after Neoadjuvant Therapy: A Cross-Sectional Study
    Location: Room 4

    Presenter: Xin Jin, MD – Fudan University Shanghai Cancer Center

  • 1:10 PM – 1:17 PM PT
    309 - Phase 1 Trial of SPECT-Guided Liver-Directed Ablative Radiotherapy for Patients with Low Functional Liver Volume
    Location: Room 4

    Presenter: Enoch Chang, MD – MD Anderson Cancer Center

  • 1:20 PM – 1:27 PM PT
    310 - Stereotactic Body Radiotherapy Combined with Sintilimab in Patients with Recurrent or Oligometastatic Hepatocellular Carcinoma: A Phase II Clinical Trial
    Location: Room 4

    Presenter: Shisuo Du, MD, PhD – Zhongshan Hospital Fudan University

  • 1:30 PM – 1:45 PM PT
    Discussant
    Location: Room 4

    Discussant: Erqi Pollom, MD, MS – Stanford University

  • 12:50 PM – 12:57 PM PT
    307 - Relationships between Microbiome and Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer
    Location: Room 4

    Presenter: Hye In Lee, MD – Seoul National University Hospital

  • 1:30 PM – 1:40 PM PT
    Discussant
    Location: Room 4

    Discussant: Kimberly Johung, MD, PhD – Yale University School of Medicine

  • 12:30 PM – 12:37 PM PT
    311 - Phase II Multi-Institutional Study of a Low-Dose (4Gy) Palliative Response-Adapted Radiotherapy Regimen for Symptomatic Bone Metastases from Multiple Myeloma: Planned Interim Analysis of First 40 Pati
    Location: Room 5

    Presenter: Leslie Ballas, MD – Cedars Sinai

  • 12:40 PM – 12:47 PM PT
    312 - Phase I Study of Bortezomib, Fludarabine, and Melphalan, with or without Total Marrow Irradiation As Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk or R
    Location: Room 5

    Presenter: Colton Ladbury, MD, BS – City of Hope National Medical Center

  • 12:50 PM – 12:57 PM PT
    313 - Predictors of Local Control with Palliative Radiotherapy for Multiple Myeloma
    Location: Room 5

    Presenter: Robert Gao, MD – Mayo Clinic

  • 1:00 PM – 1:07 PM PT
    314 - Phase 2 Trial of Anti-PD1 and 8 Gy in 1 Fraction for Relapse/Refractory Myeloma
    Location: Room 5

    Presenter: Mohammad Khan, MD, PhD – Emory University

  • 1:10 PM – 1:17 PM PT
    315 - Radiation in a New Era of Multiple Myeloma Management: Patterns of Utilization, Clinical, Radiologic, and Biochemical Outcomes, and Possible Genomic Correlates of Response
    Location: Room 5

    Presenter: Alexandra Dreyfuss, MD – Memorial Sloan Kettering Cancer Center

  • 1:20 PM – 1:27 PM PT
    316 - Clinical Outcome and Patterns of Failure in Patients with Solitary Plasmacytoma Treated with Radical Radiotherapy
    Location: Room 5

    Presenter: Ahitagni Biswas, MD, DNB, FRCR – All India Institute of Medical Sciences

  • 1:30 PM – 1:40 PM PT
    Discussant
    Location: Room 5

    Discussant: Youlia Kirova, MD – Institut Curie

  • 12:30 PM – 12:37 PM PT
    298 - Landscape of the Radiosensitizing Properties of Targeted Agents from the NCI CTEP Portfolio across Genomically Diverse 3D Tumor Models
    Location: Room 2

    Presenter: Henning Willers, MD, FASTRO – Massachusetts General Hospital

  • 12:40 PM – 12:47 PM PT
    299 - Intercellular Mechanisms of Therapeutic Resistance at the Tumor-Stromal Interface Using Ultra High-Plex Single-Cell Spatial Transcriptomics and Genetically-Engineered Tumoroids
    Location: Room 2

    Presenter: Ryan Zhao, MD

  • 12:50 PM – 12:57 PM PT
    300 - Coupling In Vivo CRISPR Perturbation with Single Cell Transcriptomics Defines Gene-Treatment Interactions and Reveals the Role of DNA-PK as a Targetable Radiation Vulnerability in Glioblastom
    Location: Room 2

    Presenter: S. John Liu, MD, PhD – UCSF

  • 1:00 PM – 1:07 PM PT
    301 - Genetically Engineered Mouse Models of CIC-DUX4 Sarcoma Reveal an Unexpected Sensitivity to Histone Deacetylase (HDAC) Inhibition
    Location: Room 2

    Presenter: Peter Hendrickson, MD, PhD – Duke University School of Medicine

  • 1:10 PM – 1:17 PM PT
    302 - Enhancing Immune-Mediated Radiotherapy Efficacy in Murine Models of Head and Neck Cancer through Peroxisome Proliferator-Activated Receptor Modulation
    Location: Room 2

    Presenter: Richard Ross, MD – University of Colorado Anschutz Medical Campus

  • 1:20 PM – 1:27 PM PT
    303 - Gamma Secretase Inhibition Sensitizes Pancreatic Adenocarcinoma Tumors to RT In Vivo
    Location: Room 2

    Presenter: Adam Mueller, MD, PhD – Thomas Jefferson University

  • 1:30 PM – 1:37 PM PT
    304 - Listeriolysin O Drives Innate and Adaptive Immune Responses to CD47 Immunotherapy
    Location: Room 2

    Presenter: Benjamin Schrank, MD, PhD – MD Anderson Cancer Center